随着免疫检查点抑制剂在妇科恶性肿瘤中的应用不断扩大，罕见的免疫相关不良事件也越来越频繁地被报道。在此，我们描述了一名患有 IIIB 期错配修复缺陷型子宫腺癌的 63 岁患者，她接受了六个周期的卡铂和紫杉醇治疗，取得了部分缓解，但疾病持续存在。然后她开始服用单药派姆单抗。经过六个周期的派姆单抗治疗后，她出现了双侧视力变化，并被诊断为后巩膜炎。帕博利珠单抗被保留，并接受口服泼尼松治疗，症状迅速缓解。完成泼尼松治疗一个月后，再次报告视力变化，她重新开始更长的口服泼尼松疗程。然后，她接受了明确的手术治疗，包括全腹腔镜子宫切除术和双侧输卵管卵巢切除术，最终病理结果为良性子宫内膜增生。她已经完成了类固醇疗程，没有任何症状。鉴于她的病理反应完全缓解，她随后被纳入监测，目前没有疾病证据。及时识别和治疗这种罕见的免疫相关不良事件可以预防潜在的永久性、使人衰弱的后果。© 2023 作者。

As Immune checkpoint inhibitors are being expanded for use in gynecologic malignancies, rare immune-related adverse events are more frequently being reported. Here we describe a 63-year-old with Stage IIIB mismatch repair deficient uterine adenocarcinoma who underwent six cycles of carboplatin and paclitaxel with partial response but persistent disease. She was then started on single agent pembrolizumab. After six cycles of pembrolizumab, she developed bilateral vision changes and was diagnosed with posterior scleritis. Pembrolizumab was held and she was treated with oral prednisone, with rapid resolution of symptoms. One month after completion of prednisone, vision changes were again reported and she was restarted on a longer oral prednisone course. She then underwent definitive surgical management consisting of a total laparoscopic hysterectomy and bilateral salpingo-oophorectomy, with final pathology of benign endometrial hyperplasia. She has completed her steroid course without any symptoms. Given her complete pathologic response, she was subsequently placed into surveillance and is currently without evidence of disease. Prompt recognition and treatment of this rare immune-related adverse event led to the prevention of potential permanent, debilitating outcomes.© 2023 The Author(s).